Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6717015 | ALMATICA | Venlafaxine besylate |
Mar, 2023
(4 days from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7776358 | ALMATICA | Extended release venlafaxine besylate tablets |
May, 2028
(5 years from now) |
Market Authorisation Date: 29 June, 2022
Treatment: Treatment of depression and generalized anxiety disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
4
United States
2
European Union
1
Australia
1
Argentina
1
South Africa
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic